ASCO: American Society of Clinical Oncology

An ongoing phase I study of patients who have experienced relapsed and/or refractory multiple myeloma has found that this population was largely able to tolerate a new oral 20S proteasome inhibitor after receiving other prior treatments.

This finding makes it clear that patients should be advised that they need to achieve a certain fitness level, and not just be told that they need to exercise. Unlike patient-reported exercise behavior, Lakoski said, fitness can be objectively and accurately measured in a clinical setting.

Half the patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who were treated with idelalisib in a phase I study experienced rapid and prolonged tumor shrinkage, a promising finding given the limited treatment choices for this group.

Results detailed today offer hope that a new form of immunotherapy will propel the bodies of some cancer patients to fight tumors, not be overrun by them, according to a study outlined at the Annual Meeting of the American Society of Clinical Oncologists (ASCO) in Chicago.

Patients in a phase III trial lived longer and experienced fewer treatment-related deaths from locally advanced non-small cell lung cancer (NSCLC) after receiving the standard dose of radiotherapy, compared to those receiving a high dose, according to a study presented today at the Annual Meeting of the American Society of Clinical Oncologists (ASCO).

Imaging spotted relapses for just a tiny fraction of patients with diffuse large B-cell lymphoma (DLBCL) before symptoms appeared, according to a new multi-institutional study, prompting recommendations that the radiation exposure of follow-up scans may not be worthwhile for all patients.